Jobs

About Nuclera

Nuclera is a next-generation DNA synthesis company creating solutions for the synthetic biology, enzyme engineering, and pharmaceutical industries. Our enzyme-mediated DNA synthesis platform will enable the rapid and cost-effective production of highly accurate, ultra-long DNA products. We are building a benchtop synthesis instrument capable of making long-length variant DNA and genome libraries for protein, biological pathway, and ultimately genome-scale engineering.

About Nuclera

Nuclera is a next-generation DNA synthesis company creating solutions for the synthetic biology, enzyme engineering, and pharmaceutical industries. Our enzyme-mediated DNA synthesis platform will enable the rapid and cost-effective production of highly accurate, ultra-long DNA products. We are building a benchtop synthesis instrument capable of making long-length variant DNA and genome libraries for protein, biological pathway, and ultimately genome-scale engineering.

Our client has developed a technology platform that enables discovery and cell line development in a range of growing markets through single cell analysis. The systems make the development of new biopharmaceuticals faster and more cost-effective, improve monoclonal antibody screening, enhance research efficiency and will offer exciting benefits to those working in diagnostics and therapeutics. Candidates must have:

The Organisation:


Innovate UK is a partner organisation within UK Research and Innovation:


UK Research and Innovation (UKRI) is a new entity that brings together nine partners to create an independent organisation with a strong voice for research and innovation, and a vision to ensure the UK maintains its world-leading position in research and innovation.


Innovate UK is the UK’s innovation agency:

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission Therapeutics is a drug discovery and development company focused on the inhibition of deubiquitylating (DUB) enzymes for treatment of diseases with high unmet need including rare mitochondrial disorders, cancer, inflammation, and neurodegeneration. The company has established a widely-applicable and proprietary DUB research platform to enable the discovery of first in class drugs.

Sosei Heptares is an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary G Protein-Coupled Receptor (GPCR) targeted StaR® technology and Structure-Based Drug Design (SBDD) platform capabilities. The company is advancing a broad and deep pipeline of partnered and in-house drug candidates in multiple therapeutic areas including neurology, immunology, immuno-oncology, gastroenterology and rare/specialty diseases.

Ensembl is seeking a computational scientist at the PhD or experienced MSc level to expand its comparative genomics capabilities.

The Ensembl project seeks a talented and motivated Project Leader to manage its activities in the area of comparative genomics.

We are seeking a highly motivated Project Leader for the UK arm of WormBase and the Alliance of Genome Resources.

Pages